ClinicalTrials.gg

Program

olipudase alfa

Also written as “rhASM”, “Olipudase alfa” and “GZ402665”.

Its studies are mostly in Niemann-Pick Diseases · Niemann-Pick Disease, Type A, led by Sanofi.

Furthest: phase 3, since Nov 26, 20136 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi60 open or runningphase 3since Nov 26, 2013Dec 11, 2006none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2006First study: phase 1 study in Niemann-Pick DiseasesFirst studyNCT00410566 · 11 enrolled · United States
  2. Nov 5, 2012Phase 1 study in Human Acid Sphingomyelinase DeficiencyNCT01722526 · 5 enrolled · United States, United Kingdom
  3. Nov 26, 2013Phase 2 study in Niemann-Pick Disease, Type ANCT02004704 · 25 enrolled · United States, Belgium, Brazil and more
  4. Nov 26, 2013Phase 3 study in Niemann-Pick Disease, Type ANCT02004691 · 36 enrolled · United States, Argentina, Australia and more
  5. Nov 7, 2014Phase 2 study in Niemann-Pick Disease, Type ANCT02292654 · 20 enrolled · United States, Brazil, France and more
  6. Apr 22, 2025Phase 2 study in Niemann-Pick DiseasesNCT06949358 · 3 enrolled · France

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06949358Niemann-Pick Diseases · France2CompletedApr 8, 20253
NCT02292654Niemann-Pick Disease, Type A · United States, Brazil, France and more2CompletedDec 9, 201920
NCT02004704Niemann-Pick Disease, Type A · United States, Belgium, Brazil and more2CompletedSep 6, 202325
NCT02004691Niemann-Pick Disease, Type A · United States, Argentina, Australia and more3CompletedMar 15, 202136
NCT01722526Human Acid Sphingomyelinase Deficiency · United States, United Kingdom1CompletedJan 20145
NCT00410566Niemann-Pick Diseases · United States1TerminatedMar 200911

How it is read

Names in the registry

  • “rhASM”, 5 entries
  • “Olipudase alfa”, 3 entries
  • “GZ402665”, 1 entry
  • “Recombinant human acid sphingomyelinase”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
olipudase alfa (Sanofi): development program | ClinicalTrials.gg